Trends in Spending on Selective Beta2 Agonists in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

35,000,000

40,000,000

45,000,000

50,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Short-acting Long-acting

© Copyright NHSBSA 2008

Trends in Usage of Selective Beta2 Agonists in General Practice in England

0

50,000,000

100,000,000

150,000,000

200,000,000

250,000,000

300,000,000

350,000,000

400,000,000

450,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

ADQ

s

Short-acting Long-acting

N.B. If no ADQ is available, the DDD has been used instead

© Copyright NHSBSA 2008

Trends in Spending on Short-acting Selective Beta2 Agonists in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Salbutamol Terbutaline Others

© Copyright NHSBSA 2008

Trends in Usage of Short-acting Selective Beta2 Agonists in General Practice in England

0

50,000,000

100,000,000

150,000,000

200,000,000

250,000,000

300,000,000

350,000,000

400,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

ADQ

s

Salbutamol Terbutaline Others

N.B. If no ADQ is available, the DDD has been used instead

© Copyright NHSBSA 2008

Trends in Spending on Long-acting Selective Beta2 Agonists in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Salmeterol Formoterol

© Copyright NHSBSA 2008

Trends in Usage of Long-acting Selective Beta2 Agonists in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

ADQ

s

Salmeterol Formoterol

© Copyright NHSBSA 2008

Trends in Spending on Selective Beta2 Agonists (by Device) in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

35,000,000

40,000,000

45,000,000

50,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Plain MDI Dry Powder Breath Actuated MDI Nebuliser Solution Non-Inhaled

© Copyright NHSBSA 2008

Trends in Usage of Selective Beta2 Agonists (by Device) in General Practice in England

0

50,000,000

100,000,000

150,000,000

200,000,000

250,000,000

300,000,000

350,000,000

400,000,000

450,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

ADQ

s

Plain MDI Dry Powder Breath Actuated MDI Nebuliser Solution Non-Inhaled

N.B. If no ADQ is available, the DDD has been used instead

© Copyright NHSBSA 2008

Trends in Spending on Antimuscarinic Bronchodilators Including Combinations in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

35,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Ipratropium Tiotropium Oxitropium Combivent® Duovent®

© Copyright NHSBSA 2008

Trends in Usage of Antimuscarinic Bronchodilators Including Combinations in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

AD

Qs

Ipratropium Tiotropium Oxitropium Combivent® Duovent®

© Copyright NHSBSA 2008

Trends in Spending on Theophylline and Aminophyllinein General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Aminophylline Theophylline

© Copyright NHSBSA 2008

Trends in Usage of Theophylline and Aminophylline in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

ADQ

s

Aminophylline Theophylline

N.B. If no ADQ is available, the DDD has been used instead

© Copyright NHSBSA 2008

Trends in Spending on Inhaled Corticosteroids (excluding Combinations) in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Beclometasone Fluticasone

Budesonide Mometasone and Ciclesonide

© Copyright NHSBSA 2008

Trends in Usage of Inhaled Corticosteroids (excluding Combinations) in General Practice in England

0

50,000,000

100,000,000

150,000,000

200,000,000

250,000,000

300,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

ADQ

s

Beclometasone Fluticasone

Budesonide Mometasone and Ciclesonide

© Copyright NHSBSA 2008

Trends in Spending on Inhaled Corticosteroids (by Device) in General Practice in England

0

20,000,000

40,000,000

60,000,000

80,000,000

100,000,000

120,000,000

140,000,000

160,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Plain MDI Dry Powder Breath Actuated MDI Nebuliser Solution

© Copyright NHSBSA 2008

Trends in Usage of Inhaled Corticosteroids (by Device) in General Practice in England

0

50,000,000

100,000,000

150,000,000

200,000,000

250,000,000

300,000,000

350,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

ADQ

s

Plain MDI Dry Powder Breath Actuated MDI Nebuliser Solution

© Copyright NHSBSA 2008

Trends in Spending on Seretide® and Symbicort®in General Practice in England

0

20,000,000

40,000,000

60,000,000

80,000,000

100,000,000

120,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Seretide® Symbicort®

© Copyright NHSBSA 2008

Trends in Usage of Seretide® and Symbicort®in General Practice in England

0

20,000,000

40,000,000

60,000,000

80,000,000

100,000,000

120,000,000

140,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

AD

Qs

Seretide® Symbicort®

© Copyright NHSBSA 2008

Trends in Prescribing of Seretide® Inhaler by Strengthin General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

100mcg/50mcg (Accuhaler) 250mcg/50mcg (Accuhaler) 500mcg/50mcg (Accuhaler)

50mcg/25mcg (Evohaler) 125mcg/25mcg (Evohaler) 250mcg/25mcg (Evohaler)

NB. Evohaler = 120 Dose Accuhaler = 60 Dose

© Copyright NHSBSA 2008

Trends in Spending on Seretide® Inhaler by Strengthin General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

35,000,000

40,000,000

45,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

100mcg/50mcg (Accuhaler) 250mcg/50mcg (Accuhaler) 500mcg/50mcg (Accuhaler)

50mcg/25mcg (Evohaler) 125mcg/25mcg (Evohaler) 250mcg/25mcg (Evohaler)

NB. Evohaler = 120 Dose Accuhaler = 60 Dose

© Copyright NHSBSA 2008

Trends in Prescribing of Leukotriene Receptor Antagonists in General Practice in England

0

50,000

100,000

150,000

200,000

250,000

300,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

Montelukast Zafirlukast

© Copyright NHSBSA 2008

Trends in Spending on Leukotriene Receptor Antagonists in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Montelukast Zafirlukast

© Copyright NHSBSA 2008

Trends in Prescribing of Non-Sedating Antihistamines in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

Cetirizine Loratadine Desloratadine Fexofenadine Levocetirizine Others

© Copyright NHSBSA 2008

Trends in Spending on Non-Sedating Antihistamines in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Cetirizine Loratadine Desloratadine Fexofenadine Levocetirizine Others

© Copyright NHSBSA 2008

Trends in Prescribing of Sedating Antihistamines in General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

Chlorphenamine Hydroxyzine Promethazine Alimemazine Brompheniramine Others

© Copyright NHSBSA 2008

Trends in Spending on Sedating Antihistamines in General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

1,800,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Chlorphenamine Hydroxyzine Promethazine Alimemazine Brompheniramine Others

© Copyright NHSBSA 2008

Trends in Prescribing of Adrenaline (BNF 3.4.3 Allergic Emergencies) in General Practice in England

0

10,000

20,000

30,000

40,000

50,000

60,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

© Copyright NHSBSA 2008

Trends in Spending on Adrenaline (BNF 3.4.3 Allergic Emergencies) in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

© Copyright NHSBSA 2008

Trends in Prescribing of Mucolytics (excluding Dornase Alfa) in General Practice in England

0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

© Copyright NHSBSA 2008

Trends in Spending on Mucolytics (excluding Dornase Alfa) in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

© Copyright NHSBSA 2008

Trends in Prescribing of and Spending on Nicotine Replacement Therapy in General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

800,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

NIC

(£)

Items NIC (£)

© Copyright NHSBSA 2008

Trends in Prescribing of Different Formulations of Nicotine Replacement Therapy in General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

Patches Inhalator Gum Lozenges S/L Tablets Nasal Spray

© Copyright NHSBSA 2008

Trends in Spending on Different Formulations of Nicotine Replacement Therapy in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Patches Inhalator Gum Lozenges S/L Tablets Nasal Spray

© Copyright NHSBSA 2008

Trends in Prescribing of and Spending on Bupropion in General Practice in England

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

40,000

45,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

NIC

(£)

Items NIC (£)

© Copyright NHSBSA 2008

Trends in Prescribing of and Spending on Varenicline in General Practice in England

0

10000

20000

30000

40000

50000

60000

70000

80000

Nov-06

Dec-06

Jan-07

Feb-07

Mar-07

Apr-07

May-07

Jun-07

Jul-07

Aug-07

Sep-07

Oct-07

Nov-07

Dec-07

Jan-08

Item

s

£0

£500,000

£1,000,000

£1,500,000

£2,000,000

£2,500,000

£3,000,000

NIC

(£)

Items NIC (£)

© Copyright NHSBSA 2008

Trends in Prescribing of NICE Drugs for Influenzain General Practice in England

0

200

400

600

800

1,000

1,200

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

Item

s

Oseltamivir Zanamivir Amantadine

© Copyright NHSBSA 2008

Trends in Spending on NICE Drugs for Influenzain General Practice in England

0

5,000

10,000

15,000

20,000

25,000

Dec-02

Mar-03

Jun-03

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Quarter to

NIC

(£)

Oseltamivir Zanamivir Amantadine

© Copyright NHSBSA 2008